NIH

Vials with medication and syringe on blue methacrylate table. Horizontal composition. Top elevated view.

January 23, 2020

Vaccine Program receives NIH renewal of VTEU

The Vanderbilt Vaccine Research Program (VVRP) has received a grant from the National Institutes of Health (NIH) to continue its work as one of the nation’s nine Vaccine and Treatment Evaluation Units (VTEUs).

By Bill Snyder

January 23, 2020

Insights on diabetic retinopathy

A drug that targets multiple pathogenic steps in diabetic retinopathy may be an ideal therapeutic strategy for the disease, Vanderbilt researchers report.

By Leigh MacMillan

January 23, 2020

HDL-cholesterol and breast cancer risk

Genetic analyses suggest that high circulating HDL-cholesterol levels may increase breast cancer risk — a surprising finding since increased HDL-cholesterol is thought to be healthy.

By Leigh MacMillan

January 23, 2020

VIGH’s Trevathan appointed to NINDS Advisory Council

Edwin Trevathan, MD, MPH, director of the Vanderbilt Institute for Global Health, has been appointed to the Advisory Council for the National Institute for Neurological Diseases and Stroke (NINDS) of the National Institutes of Health.

By Holly Fletcher

January 13, 2020

Vanderbilt-led team discovers new genetic disease and defines underlying mechanism

An international research team has discovered a new genetic syndrome caused by mutation of a single gene and named it CATIFA, an acronym for its core symptoms.

By Leigh MacMillan

January 13, 2020

Zinc uptake by a deadly pathogen

The increasingly antibiotic-resistant bacterium Acinetobacter baumannii requires zinc to cause infection, and Vanderbilt researchers have identified the zinc uptake system it uses.